Outcomes of B-Cell-Depleted Patients with Coronavirus Disease 2019 Treated with Antispike Monoclonal Antibodies

Zachary A. Yetmar, Ryan B. Khodadadi, Maria Teresa Amo Seville, Lisa Brumble, John C. O'Horo, Ravindra Ganesh, Raymund R. Razonable

Research output: Contribution to journalArticlepeer-review

Abstract

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.

Original languageEnglish (US)
Article numberofac204
JournalOpen Forum Infectious Diseases
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2022

Keywords

  • anti-CD20
  • COVID-19
  • monoclonal antibody
  • rituximab
  • SARS-CoV-2

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Outcomes of B-Cell-Depleted Patients with Coronavirus Disease 2019 Treated with Antispike Monoclonal Antibodies'. Together they form a unique fingerprint.

Cite this